Q3 2020 Brainstorm Cell Therapeutics Inc Earnings and Corporate Update Call Transcript
Greetings and welcome to the BrainStorm Cell Therapeutics' third-quarter 2020 conference call. (Operator Instructions) As a reminder, this call is recorded. And I would now like to introduce your host for today's conference, Michael Wood from LifeSci Advisors. Mr. Wood, you may begin.
Thank you, everyone, for joining the BrainStorm Cell Therapeutics earnings call. Before we begin the opening remarks, I would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding BrainStorm and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative diseases such as ALS and MS, the sufficiency of the company's existing capital resources for continuing operations in 2020 and beyond, the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, and the company's ability to develop strategic collaborations and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |